Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
6d
Medpage Today on MSNTalazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
3h
Local News Matters on MSNVacaville welcomes ‘Labyrinthine Heart’ sculpture, a gift from SF’s iconic art projectIn a different kind of heart donation, a Hearts in San Francisco sculpture has been given to the city of Vacaville, city ...
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
13h
Stockhead on MSNBiocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapyImugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells.
Oregon's bioscience sector has been growing faster than the overall economy, but proposed federal budget cuts could slow its ...
The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
GlobalData on MSN11d
Genentech eyes lupus market for Gazyva with positive Phase III data readoutGenentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results